Clinuvel Pharmaceuticals Limited Share Price Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
11:52:51 04/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 5.054 EUR | -4.64% |
|
-8.62% | -24.29% |
| 28/08 | Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10 | MT |
| 27/08 | Clinuvel Pharmaceuticals Limited, 2026 Earnings Call, Aug 27, 2026 |
| Market Cap | 42Cr 30Cr 26Cr 24Cr 22Cr 41Cr 2.83TCr 286.28Cr 111.49Cr 1.45TCr 112.55Cr 110.1Cr 4.66TCr | P/E 2027 * |
11.6x | P/E 2028 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 13Cr 9.54Cr 8.21Cr 7.71Cr 7.05Cr 13Cr 902.22Cr 91Cr 36Cr 461.07Cr 36Cr 35Cr 1.48TCr | EV / Sales 2027 * |
1.4x | EV / Sales 2028 * | 0.96x |
| Free-Float |
83.79% | Yield 2027 * |
0.66% | Yield 2028 * | 0.79% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CUV | Delayed | |
Deutsche Boerse AG
| UR9 | Delayed | |
|
OTC Markets
| CLVLF | Delayed | |
|
Berne S.E.
| UR9 | End-of-day quote | |
|
Tradegate
| UR9 | Real-time | |
|
Börse Stuttgart
| UR9 | Delayed | |
|
Boerse Muenchen
| UR9 | Real-time |
Last Transcript : Clinuvel Pharmaceuticals Limited
| 1 day | -4.64% | ||
| 1 week | -8.62% | ||
| Current month | +4.95% | ||
| 6 months | -8.46% | ||
| Current year | -24.29% |
| 1 week | 4.9 |  | 5.3 |
| 1 month | 4.9 | | 6.7 |
| Current year | 4.9 | | 7.39 |
| 1 year | 4.9 | | 7.45 |
| 3 years | 4.8 | | 10.94 |
| 5 years | 4.8 | | 27 |
| 10 years | 3.33 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.64% | -8.62% | - | - | 30Cr | |
| -1.00% | +4.43% | +49.60% | +1.42% | 8.42TCr | |
| -1.29% | +4.27% | +519.00% | +32.26% | 5.94TCr | |
| -0.73% | +1.10% | -17.37% | -35.10% | 6.05TCr | |
| -1.60% | -7.34% | -5.08% | +31.05% | 5.03TCr | |
| +0.09% | -0.54% | +9.26% | +165.71% | 4.89TCr | |
| +0.83% | +1.36% | +58.53% | -15.97% | 3.32TCr | |
| -0.64% | +0.20% | +47.19% | +97.87% | 2.59TCr | |
| +0.29% | -4.47% | +2.60% | +197.68% | 2.28TCr | |
| +1.10% | -1.67% | +64.17% | +118.01% | 1.67TCr | |
| Average | -0.78% | +0.47% | +80.88% | +65.88% | 4.47TCr | |
| Weighted average by Cap. | -0.62% | +1.40% | +95.70% | +44.95% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 9.49Cr 6.83Cr 5.87Cr 5.51Cr 5.04Cr 9.41Cr 645.29Cr 65Cr 25Cr 329.77Cr 26Cr 25Cr 1.06TCr | 10Cr 7.41Cr 6.38Cr 5.99Cr 5.48Cr 10Cr 700.81Cr 71Cr 28Cr 358.14Cr 28Cr 27Cr 1.15TCr |
| Net income | 3.6Cr 2.59Cr 2.23Cr 2.09Cr 1.91Cr 3.57Cr 244.99Cr 25Cr 9.64Cr 125.2Cr 9.73Cr 9.52Cr 403.23Cr | 3.81Cr 2.74Cr 2.36Cr 2.21Cr 2.03Cr 3.78Cr 259.16Cr 26Cr 10Cr 132.44Cr 10Cr 10Cr 426.55Cr |
| Net Debt | -28Cr -20Cr -18Cr -16Cr -15Cr -28Cr -1.93TCr -195.12Cr -76Cr -986.89Cr -77Cr -75Cr -3.18TCr | -32Cr -23Cr -20Cr -18Cr -17Cr -31Cr -2.16TCr -218.08Cr -85Cr -1.1TCr -86Cr -84Cr -3.55TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | €5.300 | 0.00% | 842 |
| 02/26/02 | €5.300 | +4.95% | 86 |
| 01/26/01 | €5.050 | 0.00% | 0 |
| 31/26/31 | €5.050 | -4.72% | 1,500 |
| 28/26/28 | €5.300 | -8.62% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
